10x Genomics Dl Stock Fundamentals
| 1KJ Stock | EUR 14.19 0.04 0.28% |
10X GENOMICS DL fundamentals help investors to digest information that contributes to 10X GENOMICS's financial success or failures. It also enables traders to predict the movement of 10X Stock. The fundamental analysis module provides a way to measure 10X GENOMICS's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to 10X GENOMICS stock.
10X |
10X GENOMICS DL Company Shares Outstanding Analysis
10X GENOMICS's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current 10X GENOMICS Shares Outstanding | 95.6 M |
Most of 10X GENOMICS's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, 10X GENOMICS DL is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, 10X GENOMICS DL has 95.6 M of shares currently outstending. This is 47.05% lower than that of the Healthcare sector and significantly higher than that of the Health Information Services industry. The shares outstanding for all Germany stocks is 83.28% higher than that of the company.
10X GENOMICS DL Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining 10X GENOMICS's current stock value. Our valuation model uses many indicators to compare 10X GENOMICS value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across 10X GENOMICS competition to find correlations between indicators driving 10X GENOMICS's intrinsic value. More Info.10X GENOMICS DL is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the 10X GENOMICS's earnings, one of the primary drivers of an investment's value.10X Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses 10X GENOMICS's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of 10X GENOMICS could also be used in its relative valuation, which is a method of valuing 10X GENOMICS by comparing valuation metrics of similar companies.10X GENOMICS is currently under evaluation in shares outstanding category among its peers.
10X Fundamentals
| Return On Equity | -0.21 | |||
| Return On Asset | -0.0892 | |||
| Profit Margin | (0.33) % | |||
| Operating Margin | (0.28) % | |||
| Shares Outstanding | 95.6 M | |||
| Shares Owned By Insiders | 2.60 % | |||
| Shares Owned By Institutions | 99.56 % | |||
| Revenue | 503.71 M | |||
| Gross Profit | 416.4 M | |||
| EBITDA | (117.15 M) | |||
| Net Income | (504.02 M) | |||
| Cash And Equivalents | 621.96 M | |||
| Cash Per Share | 5.66 X | |||
| Total Debt | 70.82 M | |||
| Debt To Equity | 0.09 % | |||
| Current Ratio | 6.69 X | |||
| Book Value Per Share | 6.78 X | |||
| Cash Flow From Operations | (219.4 M) | |||
| Earnings Per Share | (0.76) X | |||
| Target Price | 197.56 | |||
| Number Of Employees | 1.24 K | |||
| Beta | 1.67 | |||
| Market Capitalization | 5.23 B | |||
| Z Score | 43.8 |
About 10X GENOMICS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze 10X GENOMICS DL's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 10X GENOMICS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 10X GENOMICS DL based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California. 10X GENOMICS operates under Health Information Services classification in Germany and is traded on Frankfurt Stock Exchange. It employs 852 people.
Currently Active Assets on Macroaxis
Other Information on Investing in 10X Stock
10X GENOMICS financial ratios help investors to determine whether 10X Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 10X with respect to the benefits of owning 10X GENOMICS security.